The GLP-1 Telehealth State Map: Where Compounded Is Legal, Restricted, or Banned

The legality of a GLP-1 telehealth prescription in the United States depends on two states simultaneously: the state where you live and the state where the pharmacy operates. Each has its own rules. Some combinations are fine. Some are legal gray zones. A few are explicitly prohibited.

What follows is our working map of compounded GLP-1 legality by state as of early 2026. Rules change — several states are actively revising their positions — so treat this as a snapshot, not a permanent guide. Always check your specific state's most recent board action before making decisions.

The three questions that determine legality

1. Is compounding of GLP-1s allowed at all in the state where the pharmacy is located? Most states permit it under 503A rules. A handful restrict it.
2. Can an out-of-state pharmacy ship compounded drugs into your state? This depends on your state's non-resident pharmacy licensing regime.
3. Can a telehealth clinician in State A prescribe for a patient in State B? This depends on the clinician's licensure and your state's telehealth rules.

State-by-state overview

Permissive: telehealth GLP-1 fully functional

California, Texas, Florida, New York, Illinois, Pennsylvania, Georgia, Arizona, Ohio, Virginia, Washington, Colorado, Michigan, Nevada, Tennessee, North Carolina, Massachusetts, Maryland, New Jersey, Indiana, Minnesota, Missouri, Wisconsin, Oregon — compounded GLP-1 telehealth operates largely without state-level restriction. Out-of-state 503A pharmacies can ship in under standard non-resident pharmacy licensing.

Moderate: specific restrictions but still accessible

California (post-2024 updates): California tightened its non-resident pharmacy rules and requires specific disclosures for compounded GLP-1s. Most platforms adapted.

Arkansas, Idaho, Oklahoma, Alabama: Have state-specific rules about audiovisual encounters before prescription. Most major platforms comply; some smaller ones may skirt.

Hawaii, Alaska: Logistics complicate cold-chain shipping more than legal restrictions do. Some platforms don't serve these states at all.

Restrictive: compounded GLP-1 access limited

Mississippi: Tightened compounded GLP-1 rules in 2024. Many platforms stopped serving Mississippi.

Louisiana: State pharmacy board has been active in enforcement. Access is inconsistent.

Kentucky, West Virginia, South Carolina: Pharmacy board actions or state-specific rules that have limited out-of-state shipping by specific 503A operators. Coverage varies by platform.

Closely watched (rules changing)

Utah, Kansas, Iowa: Active legislative discussion of compounded GLP-1 rules. Current access is unrestricted, but could change within the year.

Tennessee: Has proposed tightening, not yet enacted as of early 2026.

The FDA shortage list shadow

The FDA moved semaglutide off its drug shortage list in February 2025 and tirzepatide earlier. When a drug is off the shortage list, 503A compounding of that drug becomes more legally restricted — pharmacies can technically only compound for "specific patient needs" not fully met by the commercial product.

What this means by state varies, because states enforce compounding differently. The federal shift created a patchwork where the same act (compounding tirzepatide for a telehealth patient) is tolerated in Florida, scrutinized in California, and potentially actionable in Mississippi.

The "personalized formulation" workaround

After the FDA shift, most compounding pharmacies added "personalized" elements to their GLP-1 formulations — semaglutide with B12, tirzepatide with glycine, etc. The argument is that the combination isn't commercially available and therefore compounding is still permitted even off the shortage list.

Whether this argument holds up in enforcement is unresolved. FDA warning letters in 2024–2025 challenged the framing in some cases. State pharmacy boards vary in how they interpret it.

Cross-state shipping: what can legally arrive at your door

Every state licenses out-of-state pharmacies through a "non-resident pharmacy permit" (or equivalent). A pharmacy in Arizona shipping to a patient in Illinois needs:

1. An active pharmacy license in Arizona.
2. A non-resident pharmacy permit in Illinois.
3. A valid prescription from a clinician licensed in Illinois (or in Arizona, depending on telehealth rules).

All three must be in place. Missing any one makes the shipment technically non-compliant, regardless of how the platform describes it.

The telehealth prescriber rule

The prescribing clinician must be licensed in your state — the state where you are at the time of the visit. This is the most commonly-bent rule in the category. Some platforms try to rely on multi-state compacts to stretch a single clinician across many states. That works for compact states and compact-enrolled clinicians. For everyone else, the clinician needs a separate license in your specific state.

Verify: when your prescription arrives, look up the prescribing clinician's NPI and state license. Confirm that clinician is licensed in your state specifically.

What happens if you move

Moving across state lines triggers a cascade:

• The clinician who prescribed for you in State A may not be licensed in State B. They may not be able to continue your prescription.
• The pharmacy may or may not have a non-resident pharmacy permit in State B.
• Your subscription platform may automatically re-route to a different clinician on its network in State B.
• If State B has different rules (e.g., requires a synchronous visit first), you may face re-intake.

We cover the full move protocol in Article #19.

The pragmatic filter

If you're shopping for a platform from a restrictive state, the right question to ask support: "Do you have a non-resident pharmacy permit in [my state]? Which pharmacy do you use for [my state] patients, and what's its license number?" Platforms that evade or deflect are telling you something. Platforms that produce answers with specifics are telling you something else.

What to expect in 2026

Two forces are reshaping the map. The FDA's compounding restrictions are tightening the federal floor. State legislatures are responding — some loosening (Texas, Florida have been relatively favorable to telehealth compounding) and some tightening (Mississippi, Louisiana, Kentucky have gone the other way).

The likely result by end of 2026: a more fragmented map, with some states where compounded GLP-1 telehealth thrives at current scale and a small-but-growing list where it's effectively unavailable. Brand-name GLP-1 telehealth (Wegovy/Zepbound through Sesame Care, LillyDirect, NovoCare) remains unaffected by any of this.